Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GASC1 Inhibitor Caffeic Acid for Advanced Squamous Esophageal Cell Cancer (ESCC): a Multicenter, Phase II Trial (GiCAEC)

NCT04648917 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Henan University of Science and Technology as lead sponsor.

NCT NCT04648917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04648917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GASC1 Inhibitor Caffeic Acid for Advanced Squamous Esophageal Cell Cancer (ESCC): a Multicenter, Phase II Trial (GiCAEC)
Lead sponsor
The First Affiliated Hospital of Henan University of Science and Technology
Phase
Phase 3
Overall status
Unknown status
Start date
May 1, 2019
Completion date
May 1, 2022
Enrollment
80 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

esophagus cancer, stage iii